[关键词]
[摘要]
目的 研究缬沙坦胶囊联合他克莫司胶囊治疗慢性肾小球肾炎的临床疗效。方法 选取2017年1月—2019年1月新疆医科大学第五附属医院收治的98例慢性肾小球肾炎患者为研究对象,将所有患者随机分为对照组和治疗组,每组各49例。对照组患者口服他克莫司胶囊,0.05 mg/(kg∙d),保持他克莫司血药浓度为10 ng/mL;治疗组患者在对照组的基础上口服缬沙坦胶囊,1粒/次,1次/d。两组患者持续治疗3个月。观察两组的临床疗效,比较两组尿素氮(BUN)、血肌酐(Scr)、尿β2-微球蛋白(β2-MG)、24 h尿蛋白定量(24 hUpro)和尿红细胞计数(RBC)水平。结果 治疗后,对照组和治疗组的总有效率分别为79.59%、95.92%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者BUN和Scr水平显著下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组肾功能指标水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者尿β2-MG、24 h Upro和尿RBC水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组β2-MG、24 h Upro和尿RBC水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论 缬沙坦胶囊联合他克莫司胶囊治疗慢性肾小球肾炎具有较好的临床疗效,能改善患者肾功能,降低BUN、Scr、尿β2-MG、24 h Upro和尿RBC水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To study the clinical effect of Valsartan Capsules combined with Tacrolimus Capsules in treatment of chronic glomerulonephritis. Methods Patients (98 cases) with chronic glomerulonephritis in Fifth Affiliated Hospital of Xinjiang Medical University from January 2017 to January 2019 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Tacrolimus Capsules, 0.05 mg/(kg·d), maintaining the blood concentration of tacrolimus at 10 ng/mL. Patients in the treatment group were po administered with Valsartan Capsules on the basis of the control group, 1 grain/time, once daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the levels of BUN, Scr, urine β2-MG, 24 h Upro and urine RBC in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.59% and 95.92%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of BUN and Scr in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the renal function indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of urine β2-MG, 24 h Upro, and urine RBC in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Valsartan Capsules combined with Tacrolimus Capsules has clinical curative effect in treatment of chronic glomerulonephritis, can improve renal function, and reduce the levels of BUN, Scr, urine β2-MG, 24 h Upro, and urine RBC, which has a certain clinical application value.
[中图分类号]
[基金项目]